Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Collegium Pharmaceutical (COLL) Non-Current Deffered Revenue (2024 - 2025)

Collegium Pharmaceutical has reported Non-Current Deffered Revenue over the past 2 years, most recently at $9.1 million for Q4 2025.

  • Quarterly results put Non-Current Deffered Revenue at $9.1 million for Q4 2025, down 8.89% from a year ago — trailing twelve months through Dec 2025 was $9.1 million (down 8.89% YoY), and the annual figure for FY2025 was $9.1 million, down 8.89%.
  • Non-Current Deffered Revenue for Q4 2025 was $9.1 million at Collegium Pharmaceutical, down from $9.3 million in the prior quarter.
  • Over the last five years, Non-Current Deffered Revenue for COLL hit a ceiling of $10.0 million in Q3 2024 and a floor of $9.1 million in Q4 2025.